PARP1 expression, activity and<i>ex vivo</i>sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott(Newcastle University), Elaine Willmore(Newcastle University)OncotargetNovember 2, 201510.18632/oncotarget.6287Cited by 30SaveCiteExport RISWatch citationsRelated PapersDNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia|Clinical Cancer Research|2008|91Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling|Cancers|2023|4